Sobi is a global biopharma company transforming the lives of people with rare and debilitating diseases.
Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia.
In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm.
Q2 report 2025
Sobi published its Q2 report on 16 July.
VALIANT Phase 3 Data in Nephrology
Sobi hosted an investor conference call on 12 June to discuss the 52-week Phase 3 VALIANT data for Aspaveli® in nephrology, following a presentation at the ERA Congress.
Loading...
Press releases
Upcoming events
Loading...